Hemogenyx Pharmaceuticals (LON:HEMO) Shares Up 5.5% – Should You Buy?

Hemogenyx Pharmaceuticals Plc (LON:HEMO)’s stock price traded up 5.5% on Thursday. The stock traded as high as GBX 480 and last traded at GBX 480. Approximately 6,344 shares changed hands during trading, a decline of 73% from the average daily volume of 23,572 shares. The stock had previously closed at GBX 455.

Hemogenyx Pharmaceuticals Trading Up 5.5%

The business has a 50 day moving average of GBX 587.77 and a 200-day moving average of GBX 743.03. The company has a current ratio of 1.38, a quick ratio of 6.72 and a debt-to-equity ratio of 167.66. The firm has a market capitalization of £32.64 million, a P/E ratio of -2.81 and a beta of 1.49.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.